May 30, 2019 - Novartis' new gene therapy, Zolgensma, may be the most expensive drug ever, but there's much more to the story.
May 27, 2019 - Novartis (NVS) obtains FDA approvals for a breast cancer drug and a gene therapy for pediatric patients.
May 27, 2019 - Incyte (INCY) obtains FDA approval for a third indication of lead drug, Jakafi, for the treatment of GVHD.
May 26, 2019 - Getting end payers on board with a seven-figure price for Zolgensma won't be easy.
May 24, 2019 - A $2.1 million price tag could make Zolgensma a blockbuster medicine for these companies.
May 23, 2019 - Novartis (NVS) reports encouraging data on combination asthma drug. The company also highlights its growth plans at its annual meet.
May 20, 2019 - Adverum's (ADVM) stock gains as the FDA lifts the clinical hold on the second cohort of an initial stage study on lead candidate.
May 17, 2019 - KBC Group NV (OTCPK:KBCSF) Q1 2019 Results Conference Call May 16, 2019 03:30 AM ET Company Participants Kurt De Baenst - Investor Relations Johan Thijs - CEO Rik Scheerlinck - CFO Conference Call Par
May 17, 2019 - The following slide deck was published by KBC Group NV in conjunction with their 2019 Q1 earnings call.
May 16, 2019 - Slow Capital, Inc. Buys Kezar Life Sciences Inc, Qiagen NV, iShares 20+ Year Treasury Bond ETF, Sells Qualcomm Inc, iShares Preferred and Income Securities ETF, Facebook Inc, Stocks: KZR,NVDA,AGG,SCHZ,NEE,MDB,QGEN,TLT,MBB,ADBE,ADI,WD, release date:May 16, 2019